MS patients switch meds: will a cheaper option work just as well?
NCT ID NCT07235644
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at people with relapsing-remitting multiple sclerosis who switched from the drug MabThera to a similar, lower-cost medicine called Rixathon. Researchers want to see if the switch changes signs of nerve damage, new brain lesions, relapses, or disability. They will review medical records from 184 patients at Uppsala University Hospital to compare health data before and after the switch.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rituximab (biosimilar Rixathon)
- What this could lead to
- If successful, this study could show that switching to a cheaper biosimilar is just as safe and effective, potentially lowering treatment costs for MS patients.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. It only looks at a small group at one hospital, so findings may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MS (MULTIPLE SCLEROSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Uppsala University Hospital
Uppsala, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentle electric zap to the brain restore memory in MS?
- Brain scans to reveal if new MS drug quietly calms inflammation
- Brain scans may reveal how MS drug affects mental fatigue
- Brain scans could reveal which MS drugs fight mental exhaustion
- Could a lighter MS treatment keep the disease at bay?
- Brain shrinkage as a crystal ball for MS progression?